Determination of tumor receptor status and proliferative activity by immunohistochemistry (ER, PR, Ki-67)
Assessment of tumor receptor status and proliferative activity by immunohistochemistry (IHC) (ER, PR, Ki-67) is a key diagnostic test in oncologic pathology, allowing assessment of the tumor's hormonal sensitivity and biological aggressiveness.
The test is most commonly used for breast tumors and plays a crucial role in selecting the treatment strategy, including the need for hormonal therapy and determining the disease prognosis.
What is Assessed
- Estrogen receptors (ER) determine the tumor's sensitivity to estrogen.
- Progesterone receptors (PR) reflect the hormonal dependence of the tumor and the functional activity of ER.
- Ki-67 is a marker of proliferative activity and characterizes the tumor growth rate.
- Comprehensive assessment of these markers allows classification of the tumor by molecular subtype and determination of its prognosis.
Biomaterial: paraffin block